Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKesson
Colorcon
Merck
AstraZeneca

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

Patent: 7,560,436

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,560,436
Title:Methods of treating gastrointestinal inflammation
Abstract: The present invention provides methods of treating gastrointestinal inflammation, methods of treating inflammatory bowel disease, methods of treating Crohn\'s Disease, and methods of treating ulcerative colitis in an individual. The methods generally involve administering an effective amount of an agent that increases the level of a Type I interferon and/or that activates a Type I interferon signaling pathway in the individual.
Inventor(s): Raz; Eyal (Del Mar, CA), Katakura; Kyoko (San Diego, CA), Lee; Jongdae (San Diego, CA), Rachmilewitz; Daniel (Tel Aviv, IL)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:11/359,945
Patent Claims:see list of patent claims

Details for Patent 7,560,436

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 1998-08-24 ⤷  Try it Free 2025-02-22
Immunex Corporation ENBREL etanercept For Injection 103795 1998-11-02 ⤷  Try it Free 2025-02-22
Immunex Corporation ENBREL etanercept For Injection 103795 1999-05-27 ⤷  Try it Free 2025-02-22
Immunex Corporation ENBREL etanercept Injection 103795 2004-09-27 ⤷  Try it Free 2025-02-22
Immunex Corporation ENBREL etanercept Injection 103795 2007-02-01 ⤷  Try it Free 2025-02-22
Immunex Corporation ENBREL MINI etanercept Injection 103795 2017-09-14 ⤷  Try it Free 2025-02-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Medtronic
Moodys
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.